Innate lymphoid cells and cancer

Area of Science:

• Immunology
• Cancer Biology
• Cellular Biology

Background:

• Innate lymphoid cells (ILCs), including NK cells, ILC1, ILC2, and ILC3, are crucial for immune responses against pathogens and transformed cells.
• Tissue-resident ILC subsets are influenced by their organ environment, exhibiting diverse functions from tissue repair to immunopathology and cancer promotion.
• Emerging evidence suggests non-NK ILCs may possess anti-tumor potential, challenging previous notions of their predominantly tumorigenic roles.

Purpose of the Study:

• To investigate the complex and often paradoxical roles of ILCs in the context of cancer.
• To explore the potential of non-NK ILCs in driving anti-tumor immune responses.
• To identify knowledge gaps and new therapeutic avenues for targeting ILCs in cancer immunotherapy.

Main Methods:

• Review and synthesis of existing literature on ILC function in cancer.
• Analysis of ILC subset behavior in different tissue microenvironments.
• Exploration of emerging data on non-NK ILCs and anti-tumor immunity.

Main Results:

• ILCs display pleiotropic effects in cancer, contributing to both tissue repair and potentially promoting tumorigenesis or immunopathology.
• Non-NK ILCs are increasingly recognized for their potential to elicit anti-tumor responses, contrary to some prior assumptions.
• Significant gaps in understanding ILC behavior in cancer remain, highlighting the need for further research.

Conclusions:

• ILCs represent a promising, yet complex, target for cancer immunotherapy.
• Further research into the specific roles and modulation of ILC subsets is essential for developing novel therapeutic strategies.
• Harnessing the anti-tumor capabilities of ILCs offers a new horizon for cancer treatment.